The Diagnostic Value Of Serum HE4 And CA125 In Serous Ovarian Carcinoma By Single And Combined Detection

Objectives:To study the expression of HE4 and CA125 in venous blood samples of patients with serous ovarian cancer, and to explore the diagnostic value of CA125 and HE4 in serous ovarian carcinoma separately and in combination.Methods:1.HE4 and CA125 levels in serum of serous ovarian cancer 87 cases, benign ovarian tumor 77 cases and healthy women 52 cases are detected by using the Roche electrochemical luminescence apparatus. Cancer,benign tumor patients from Liaocheng People's Hospital,Department of Obstetrics and Gynecology,health check body women from the health center.2. To compare the clinical value of serum HE4 and CA125 in the diagnosis of serous ovarian cancer3. Analysis of the connection between HE4,CA125 and pathological characteristics of serous ovarian carcinoma.4. HE4 and CA125 results are the mean+standard deviation (x+s) with the SPSS statistical analysis,, samples were compared by ANOVA or t test, the diagnosis of HE4 and CA125 is produced by receiver operating characteristic curve (ROC curve) to carry on the analysis.5. Select the imageology (CT/MR), pathology (ovarian puncture) and serum ovarian tumor markers (HE4/CA125), and compare the economic benefits of these three methods.Results:1.Serous ovarian cancer serum HE4 (631.92 pmol/L),CA125 (784.17 pg/ ml) level is significantly higher than that of benign ovarian neoplasms group and the health check group.which has statistical significance? For CA125 the benign ovarian neoplasms group and the health check group has great significant difference,For HE4 the benign ovarian neoplasms group and the health check group has no significant difference.2.For HE4 the sensitive and specific diagnosis of ovarian cancer, are 86.1%,90.3%,the detection of CA125 sensitivity and specificity are 85.4%, 65.6%.Combined detection of these two indicators of sensitivity and specificity are 96.3%,94.1%,and the cooperative detection by receiver operating curve (ROC) area is greater than that of HE4 and CA125 separately (P< 0.05).3. Advanced ovarian cancer (III and IV) of serum HE4 (778.27pmoL/L)is higher than the early stage of ovarian cancer (stage ?,?) serum HE4 (380.31 pmoL/L),HE4 level and clinical pathological stage is positively correlated (P<0.05),the later stage, the higher the level.There is nothing to do with the age, differentiation degree,ascites and lymph node metastasis.The level of Ca125 and degree of differentiation is positively correlated (P<0.05), the lower stage, the higher the level.There is nothing to do with the clinical stage, age.the invasion of lymph node and ascites formation.4. There was no significant difference in the level of HE4 and CA125 in the patients with ovarian cancer before and after menopause.5. From the cost comparison, the most economic is human epididymis protein 4 and carbohydrate antigen 125; from the time, the two indexes for screening are the least; from the comparison of the extent of the damage, the two indexes have the minimal wound.Conclusion:1. HE4 in the differential diagnosis of benign ovarian neoplasms and malignant tumor specificity is better than CA125,which is expected to become an important reference index for the diagnosis of serous ovarian cancer.2. The cooperative screening of CA125 and HE4 can promote the accuracy of ovarian cancer,which has better clinical reference value.3 The level of HE4 expression was related to the clinical stage of ovarian cancer, the later stage, the higher the level. The level of CA125 and degree of differentiation is positively correlated (P<0.05), the lower stage, the higher the level.4. In terms of economic benefits, the screening of the joint human epididymis protein 4 and carbohydrate antigen 125 is superior to imageology and pathology...